Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 56 entries
View as:

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL

Phase: N/A Priority: Normal
NCT ID: NCT03593018 Org: User:
Start: 11/09/18 End: 12/31/25 Due: 12/31/26

Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT03104478 Org: User:
Start: 05/09/17 End: 09/04/21 Due: 09/04/22

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT03276468 Org: User:
Start: 02/12/18 End: 08/24/22 Due: 08/24/23

Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

Phase: N/A Priority: Normal
NCT ID: NCT04974216 Org: User:
Start: 12/20/21 End: 12/31/26 Due: 12/31/27

GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01659099 Org: User:
Start: 09/30/12 End: 12/31/17 Due: 12/31/18

Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years

Phase: N/A Priority: Normal
NCT ID: NCT01195714 Org: User:
Start: 05/31/10 End: 04/30/14 Due: 04/30/15

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04842877 Org: User:
Start: 06/11/21 End: 10/31/26 Due: 10/31/27

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03225924 Org: User:
Start: 07/26/17 End: 10/18/19 Due: 10/18/20

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT04531046 Org: User:
Start: 03/10/21 End: 06/30/26 Due: 06/30/27

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.

Phase: N/A Priority: Normal
NCT ID: NCT02292979 Org: User:
Start: 03/31/15 End: 06/02/22 Due: 06/02/23

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01393756 Org: User:
Start: 12/31/10 End: 11/30/15 Due: 11/30/16

Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients

Phase: N/A Priority: Normal
NCT ID: NCT01285765 Org: User:
Start: 12/31/10 End: 05/23/20 Due: 05/23/21

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT07018752 Org: User:
Start: 08/31/25 End: 01/31/30 Due: 01/31/31

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

Phase: N/A Priority: Normal
NCT ID: NCT02686346 Org: User:
Start: 03/31/16 End: 07/12/21 Due: 07/12/22

Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP

Phase: N/A Priority: Normal
NCT ID: NCT01122472 Org: User:
Start: 04/30/09 End: 09/30/19 Due: 09/30/20

Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03603847 Org: User:
Start: 08/02/18 End: 06/16/23 Due: 06/16/24

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01796002 Org: User:
Start: 01/31/13 End: 12/13/22 Due: 12/13/23

Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03892525 Org: User:
Start: 07/04/19 End: 04/07/21 Due: 04/07/22

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

Phase: N/A Priority: Normal
NCT ID: NCT02896582 Org: User:
Start: 11/29/16 End: 12/02/24 Due: 12/02/25

Detection and Characterization of Residual Masses in Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT02300402 Org: User:
Start: 10/31/14 End: 12/31/22 Due: 12/31/23

A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01877005 Org: User:
Start: 07/04/13 End: 06/12/18 Due: 06/12/19

BRIEF Bendamustine and Rituximab In Elderly Follicular

Phase: N/A Priority: Normal
NCT ID: NCT01313611 Org: User:
Start: 02/28/11 End: 12/31/17 Due: 12/31/18

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04703686 Org: User:
Start: 03/30/21 End: 03/01/26 Due: 03/01/27

A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT01280526 Org: User:
Start: 01/31/11 End: 03/31/14 Due: 03/31/15

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Phase: N/A Priority: Normal
NCT ID: NCT03496779 Org: User:
Start: 04/10/18 End: 10/08/22 Due: 10/08/23